

Unique Technology
Based on fully human synthetic phage display librairies

Best in class scientific expertise
International research team with over 100 years of combined expertise

Proprietary antibody
Outstanding human antibodies assets available for partnering and licensing

TECHNOLOGY
- Proprietary synthetic Ab library
- In vitro screening methods validated on:
- - Integral membrane proteins
- - Soluble proteins
- - Peptides
PIPELINE
- Innovative therapeutics antibodies with unique pH sensitive properties for oncology
- Full adaptability to various pharmaceutical development formats: ADC, TCE, CAR-T…


ABOUT US
Mabqi, founded upon best
in class technology from Inserm,
is a biotech company with an integrated
approach to develop human antibodies.

LATEST NEWS
Mabqi contributed to the article « Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis » published in the journal Nature Communications on August 31, 2023.
Mabqi is proud to have contributed to the article "Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis" published in the journal Nature Communications on August 31, 2023.This study was conducted in collaboration with Laboratoires Servier. You can access the article by clicking on this link.
Mabqi moved!
More labs and office space for delivering outstanding antibodies in Montpellier! Our new address is: CAP SIGMA - ZAC Euromédecine II - 1682 Rue de la Vaslière - 34790 Grabels, France
Join us at Festival of Biologics 2023
Come and visit Mabqi during the Festival of Biologics (FOB) in Basel, Switzerland - October 10-12, 2023. Click here to get all the information.